RSA Announces New Solution to Enhance Security for Microsoft Entra ID
13.11.2025 13:00:00 CET | Business Wire | Press release
RSA, the security-first identity leader, announced today that RSA® ID Plus for Microsoft, a new solution category that provides an enhanced security layer for Microsoft Entra ID, is now generally available. Now on the Microsoft Azure Marketplace, the first product, RSA ID Plus M1, includes key capabilities that defend organizations from emerging attacks and help them maintain operational continuity in both Microsoft and non-Microsoft environments.
RSA ID Plus for Microsoft M1:
- Protects resources within and beyond the Microsoft ecosystem: RSA ID Plus provides total coverage for legacy, OT, Microsoft, and non-Microsoft environments, bringing modern MFA and passwordless to data centers, mainframes, macOS, AD-joined devices, Entra-joined PCs and servers (including older OS versions), and other web servers and critical infrastructure that Entra alone can’t reach.
- Ensures mission-critical resources are always available and always protected: RSA’s unique Hybrid HA architecture and offline capabilities ensure that mission-critical on-prem resources and off-network laptops are always available and always protected even when cloud services are unreachable.
- Stops attacks that bypass MFA: RSA Help Desk Live Verify stops attacks targeting IT help desk personnel and users. The patent-pending technology uses phishing-resistant, passwordless identity assurance to stop attackers from exploiting weak enrollment and credential processes to launch attacks.
- Integrates seamlessly with Microsoft: RSA ID Plus works in tandem with Microsoft Entra ID Plan 1 and Plan 2 to close security gaps without complexity.
“High-security industries have unique infrastructures that demand security expertise to maintain operations and defend against new threats,” said RSA CEO Greg Nelson. “RSA ID Plus for Microsoft ensures that banks, hospitals, government agencies, and powerplants can deploy modern security solutions to defend themselves from emerging threats while still ensuring resilient operations.”
“The extraordinary risks that financial services, healthcare, energy, and other highly regulated industries face demand the extraordinary security capabilities that only RSA and Microsoft together can deliver,” said Laura Marx, RSA Chief Marketing and Growth Officer. “With the layered security approach from both RSA and Microsoft, organizations get both the scaled cloud infrastructure and deep identity security expertise they need to stop AI-powered threats, remain operational, and ensure that all users can stay productive.”
Users are invited to demo RSA ID Plus for Microsoft next week at Microsoft Ignite Booth #1826R.
Resources:
RSA ID Plus for Microsoft data sheet
Join RSA at Microsoft Ignite Booth #1826R
Get RSA ID Plus on the Microsoft Azure Marketplace
About RSA:
RSA provides mission-critical cybersecurity solutions that protect the world’s most security-sensitive organizations. The RSA Unified Identity Platform provides true passwordless identity security, risk-based access, automated identity intelligence, and comprehensive identity governance across cloud, hybrid, and on-premises environments. More than 9,000 high-security organizations trust RSA to manage more than 60 million identities, detect threats, secure access, and enable compliance. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251113424287/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom